Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria
- Findings support positive proof of mechanism, through successful degradation of methionine, precursor to homocysteine, using dietary disease model in preclinical models and healthy volunteer study
- 02/02/2024
|
Synlogic Provides Corporate Update and Outlook for 2024
- - Data review from pivotal Synpheny-3 study in PKU expected in H1 2024, with potential to expand study population to patients aged 12-17 years of age -
- 01/04/2024
|
Synlogic Announces Contract with the Air Force Research Lab
- - Selection of Synlogic reflects Company's leadership in process development and manufacturing of therapeutics based on synthetic biology - - Selection of Synlogic reflects Company's leadership in process development and manufacturing of therapeutics based on synthetic biology -
- 12/27/2023
|
Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023
- - Poster presentation on SYNB1353 program for homocystinuria includes findings from process improvements to improve activity of methionine degradation -
- 12/07/2023
|
Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- - Underwritten public offering of $21.0 million and earned $2.5 million milestone payment from Roche have extended cash runway into the first half of 2025 -
- 11/09/2023
|
Synlogic, Inc. (SYBX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
- Synlogic, Inc. (SYBX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 11/02/2023
|
Synlogic Announces Closing of $21.0 Million Underwritten Public Offering
- CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced the closing of its previously announced underwritten public offering.
- 10/03/2023
|
Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering
- CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced the pricing of an underwritten public offering of (i) 7,394,363 shares of common stock (or common stock equivalents in lieu thereof) and (ii) accompanying common warrants to purchase up to an aggregate of 7,394,363 shares of common stock. The combined effective offering price to the public of each share of common stock (or pre-funded warrant) and accompanying warrant is $2.84. The accompanying warrants will have an exercise price of $3.408 per share, will be exercisable immediately, and will expire five years from the initial exercise date. All of the securities are being offered by Synlogic, Inc. The Company expects to receive total gross proceeds of approximately $21.0 million, before deducting underwriting discounts, commissions and offering expenses. The offering is expected to close on or about October 3, 2023, subject to satisfaction of customary closing conditions.
- 09/29/2023
|
Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism
- CAMBRIDGE, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced the publication of results from its Synpheny-1 Phase 2 study of its drug candidates, labafenogene marselecobac (SYNB1934) and SYNB1618 in patients with phenylketonuria (PKU) in the journal Nature Metabolism.
- 09/28/2023
|
Why Is Synlogic (SYBX) Stock Down 6% Today?
- Synlogic (NASDAQ: SYBX ) stock is sliding lower on Thursday after the biopharmaceutical company announced a reverse split for its shares. According to a press release from Synlogic, the company enacted a reverse stock split after markets closed yesterday.
- 09/28/2023
|
Synlogic Announces Reverse Stock Split
- CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced that it will implement a 1-for-15 Reverse Stock Split of its common stock (Reverse Stock Split), effective at 5:00 p.m. Eastern Time on Wednesday, September 27, 2023. The Reverse Stock Split, which was approved by shareholders at the company's Annual Meeting of Stockholders on September 21, 2023, is primarily intended to bring the company into compliance with the minimum bid price requirement for maintaining its listing on The Nasdaq Capital Market. Beginning with the opening of trading tomorrow, Thursday, September 28, 2023, the company's common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under the existing symbol “SYBX” and a new CUSIP number 87166L 209.
- 09/27/2023
|
Synlogic to Participate in Chardan's Genetic Medicines Conference
- CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced its management team will participate in Chardan's 7th Annual Genetic Medicines Conference, being held in New York, October 2-3, 2023. In addition to one-on-one meetings with investors, Synlogic CEO Dr. Aoife Brennan will participate in a Fireside Chat on Monday, October 2 at 4:30 p.m. Eastern Time.
- 09/21/2023
|
Synlogic Announces CEO Aoife Brennan Named to PharmaVoice 100
- CAMBRIDGE, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced that CEO Aoife Brennan, M.B. Ch.B., has been honored as a PharmaVoice 100 winner, a list recognizing the most inspiring people in the life sciences industry.
- 09/19/2023
|
Synlogic, Inc. (SYBX) Reports Q2 Loss, Misses Revenue Estimates
- Synlogic, Inc. (SYBX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.22 per share a year ago.
- 08/10/2023
|
Synlogic to Present at the Jefferies Global Healthcare Conference
- CAMBRIDGE, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that Aoife Brennan, M.B. Ch.B., President and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference being held in New York, NY, June 7-9, 2023.
- 05/23/2023
|
3 Penny Stocks That Could Turn $1,000 into $10,000 in a Year
- Turning $1,000 into $10,000 in a year in the stock market is undoubtedly a lofty goal. Make no bones about it, it's not particularly likely to happen.
- 05/11/2023
|
Synlogic, Inc. (SYBX) Reports Q1 Loss, Lags Revenue Estimates
- Synlogic, Inc. (SYBX) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.22 per share a year ago.
- 05/11/2023
|
3 Megatrend Stocks to Buy for 10x Potential Returns
- Megatrends exist across many thematic areas of the stock market. Identifying these trends usually involves analyzing key factors such as technological breakthroughs, social change, urbanization, climate change, and global wealth shifts and capitalizing on them.
- 04/28/2023
|
Synlogic, Inc. (SYBX) Reports Q4 Loss, Misses Revenue Estimates
- Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 7.69% and 73.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 03/29/2023
|
Synlogic, Inc. (SYBX) Upgraded to Buy: Here's Why
- Synlogic, Inc. (SYBX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 01/16/2023
|
Synlogic, Inc. (SYBX) Reports Q3 Loss, Tops Revenue Estimates
- Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of -8.70% and 93.71%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/10/2022
|
Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q2 2022 Results - Earnings Call Transcript
- Synlogic, Inc. (NASDAQ:SYBX ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Andrew Funderburk - Kendall IR Aoife Brennan - CEO, President Michael Jensen - CFO Tony Awad - COO Molly Harper - Chief Business Officer Dave Hava - Chief Scientific Officer Conference Call Participants Joseph Schwartz - SVB Securities Mark Breidenbach - Oppenheimer Mitchell Kapoor - H.C. Wainwright Operator Good morning.
- 08/11/2022
|
Synlogic, Inc. (SYBX) Reports Q2 Loss, Lags Revenue Estimates
- Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 4.35% and 49.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/11/2022
|
Synlogic to Present at the 2022 National PKU Alliance (NPKUA) Conference
- VANCOUVER, Wash., June 28, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, announced today it will participate at the National PKU Alliance's (NPKUA) biennial conference July 7-10, 2022 in Vancouver, Washington. As an event sponsor, Synlogic has been invited to present during the session “What's New in PKU? (Emerging Therapies, Research, Foods & Beyond).” In addition, the team will share data on dietary protein intake in PKU patients during a poster presentation.
- 06/28/2022
|
Synlogic to Present at the 2022 HCU Network America, Organic Acidemia Association and Propionic Acidemia Foundation Conference
- BETHESDA, Md., June 21, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, announced it will participate in the HCU Network America, Organic Acidemia Association and Propionic Acidemia Foundation 2022 Conference, in Bethesda, Maryland, June 25-26, 2022. Synlogic has been invited to present a poster to patients and families affected by homocystinuria (HCU) regarding SYNB1353, an investigational oral therapy designed to consume methionine for the potential treatment of HCU.
- 06/21/2022
|
Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q1 2022 Results - Earnings Call Transcript
- Synlogic, Inc. (NASDAQ:SYBX ) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Andrew Funderburk - Kendall Investor Relations Aoife Brennan - Chief Executive Officer, President Molly Harper - Chief Business Officer Dave Hava - Chief Scientific Officer Michael Jensen - Chief Financial Officer Tony Awad - Chief Operating Officer Conference Call Participants Keay Nakae - Chardan Mark Breidenbach - Oppenheimer Operator Good morning, and welcome to Synlogic's First Quarter 2022 Conference Call. At this time all participants are in a listen-only mode.
- 05/12/2022
|
Synlogic, Inc. (SYBX) Reports Q1 Loss, Misses Revenue Estimates
- Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 4.35% and 51.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/12/2022
|
Synlogic to Present Data on Phenylketonuria and Homocystinuria Programs at the Society for Inherited Metabolic Disorders 43rd Annual Meeting
- CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced that data from its phenylketonuria (PKU) and homocystinuria (HCU) programs will be highlighted in two poster presentations at the Society for Inherited Metabolic Disorders (SIMD) 43rd Annual Meeting being held April 10-13, 2022 in Orlando, Florida.
- 04/01/2022
|
Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q4 2021 Results - Earnings Call Transcript
- Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q4 2021 Results - Earnings Call Transcript
- 03/17/2022
|
Synlogic, Inc. (SYBX) Reports Q4 Loss, Misses Revenue Estimates
- Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 22.22% and 1.33%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 03/17/2022
|
Synlogic Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast
- CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced the Company will release its fourth quarter and full year 2021 financial results before the market opens on Thursday, March 17, 2022. The press release will be followed by a conference call at 8:30 am ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a corporate update.
- 03/10/2022
|
What Makes Synlogic, Inc. (SYBX) a New Buy Stock
- Synlogic, Inc. (SYBX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 12/24/2021
|
Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q3 2021 Results - Earnings Call Transcript
- Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q3 2021 Results - Earnings Call Transcript
- 11/10/2021
|
Synlogic, Inc. (SYBX) Reports Q3 Loss, Tops Revenue Estimates
- Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 0.00% and 233.09%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/10/2021
|
Synlogic Presents Data on Hyperoxaluria Program at American Society of Nephrology Kidney Week 2021
- CAMBRIDGE, Mass., Oct. 15, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced two poster presentations at the upcoming American Society for Nephrology (ASN) Kidney Week 2021, to be held virtually November 4 – 7th, 2021.
- 10/15/2021
|
Synlogic Appoints Molly Harper as Chief Business Officer
- CAMBRIDGE, Mass., Sept. 27, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the appointment of Molly Harper as Chief Business Officer.
- 09/27/2021
|
Synlogic Announces Pricing of Public Offering of Common Stock
- CAMBRIDGE, Mass., Sept. 22, 2021 /PRNewswire/ -- Synlogic (Nasdaq: SYBX) a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the pricing of its underwritten public offering of 15,000,000 shares of its common stock at a public offering price of $3.00 per share.
- 09/22/2021
|
Synlogic Announces Proposed Public Offering of Common Stock
- CAMBRIDGE, Mass., Sept. 22, 2021 /PRNewswire/ -- Synlogic (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it has commenced an underwritten public offering of its common stock.
- 09/22/2021
|
Why Are Synlogic Shares Moving Higher Premarket Monday?
- Synlogic Inc (NASDAQ: SYBX) has announced data from clinical studies evaluating SYNB1618 and SYNB1934 for phenylketonuria (PKU). PKU is a rare genetic disease that manifests at birth and is characterized by an inability to break down phenylalanine, an amino acid commonly found in many foods.
- 09/20/2021
|
SYBX Stock: Why It Increased Today
- The stock price of Synlogic Inc (NASDAQ: SYBX) increased by over 7% pre-market today. This is why it happened.
- 09/20/2021
|
Synlogic Announces Positive Phase 2 Data Demonstrating Reduction in Plasma Phenylalanine Levels in Patients with Phenylketonuria
- CAMBRIDGE, Mass., Sept. 20, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced positive data from clinical studies evaluating both SYNB1618 and SYNB1934, investigational Synthetic Biotic™ medicines for the treatment of phenylketonuria (PKU).
- 09/20/2021
|
Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting
- CAMBRIDGE, Mass., Sept. 10, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it will present data on SYNB8802, an investigational Synthetic Biotic medicine for the treatment of Enteric Hyperoxaluria (HOX), during the American Urological Association (AUA) Annual Meeting, being held virtually September 10 – 13th.
- 09/10/2021
|
Synlogic Presents at Global PKU Patient Meeting
- CAMBRIDGE, Mass., Sept. 10, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented on the development of investigational Synthetic Biotic medicines for the treatment of Phenylketonuria (PKU) at the Global PKU Patient Meeting, being held virtually September 10-11 th, 2021.
- 09/10/2021
|
Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q2 2021 Results - Earnings Call Transcript
- Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q2 2021 Results - Earnings Call Transcript
- 08/12/2021
|
Synlogic, Inc. (SYBX) Reports Q2 Loss, Tops Revenue Estimates
- Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 3.45% and 23.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/12/2021
|
Synlogic Reports Second Quarter Financial Results and Provides Business Update
- CAMBRIDGE, Mass., Aug. 12, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today reported financial results for the second quarter ended June 30, 2021, and provided an update on its clinical and preclinical programs.
- 08/12/2021
|
Synlogic Announces Second Quarter 2021 Conference Call & Participation in Upcoming Banking Conference
- CAMBRIDGE, Mass., Aug. 5, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Company will release its second quarter 2021 financial results before the market opens on Thursday, August 12, 2021.
- 08/05/2021
|
Synlogic Publishes Papers in Nature Journals Demonstrating Proof-of-Mechanism and Potential of Synthetic Biotic Platform for the Treatment of Phenylketonuria (PKU)
- CAMBRIDGE, Mass., July 22, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced today the publication of two papers in the journals Nature Metabolism and Communications Biology.
- 07/22/2021
|
Synlogic's (SYBX) Begins Phase I Study for PKU Treatment
- Synlogic (SYBX) initiates phase I study of SYNB1934, a synthetic biotic candidate to treat PKU. The drug is an evolved strain of SYNB1618, another PKU candidate currently undergoing phase II study.
- 07/16/2021
|
Synlogic Announces Initiation of Phase 1 Study of SYNB1934, a Next-Generation Strain for the Treatment of Phenylketonuria (PKU)
- CAMBRIDGE, Mass., July 15, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it has initiated the Phase 1 clinical trial of SYNB1934, an investigational Synthetic Biotic™ medicine for the treatment of Phenylketonuria (PKU).
- 07/15/2021
|
Synlogic Enters Research Collaboration with Roche for Development of Novel Therapy to Treat Inflammatory Bowel Disease
- CAMBRIDGE, Mass., June 17, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced today that it has entered into a research collaboration agreement with Roche for the discovery of a novel Synthetic Biotic™ medicine for the treatment of inflammatory bowel disease (IBD).
- 06/17/2021
|
Synlogic Presents Additional Preclinical Data on Therapeutic Candidates SYNB1934 for Phenylketonuria (PKU) and SYNB8802 for Enteric Hyperoxaluria at Synthetic Biology: Engineering, Evolution & Design (SEED) Conference
- CAMBRIDGE, Mass., June 15, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented on the development of the investigational Synthetic Biotic medicine™ SYNB8802 for the treatment of Enteric Hyperoxaluria and on SYNB1934, an evolved strain of Synthetic Biotic medicine SYNB1618, for the treatment of Phenylketonuria (PKU) during the Synthetic Biology: Engineering, Evolution & Design (SEED) conference, being held virtually June 15-18, 2021.
- 06/15/2021
|
Synlogic to Present at Upcoming Virtual Banking and Industry Conference
- CAMBRIDGE, Mass., May 25, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife Brennan, M.B.
- 05/25/2021
|
Synlogic Presents Data at Digestive Disease Week (DDW) on a Novel Approach for the Treatment of Inflammatory Bowel Disease
- CAMBRIDGE, Mass., May 23, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented data on an investigational program to develop Synthetic Biotic™ medicines for the treatment of inflammatory bowel disease (IBD) during Digestive Disease Week (DDW), being held virtually May 21-23, 2021.
- 05/23/2021
|
Synlogic, Inc. (SYBX) CEO Dr. Aoife Brennan on Q1 2021 Results - Earnings Call Transcript
- Synlogic, Inc. (SYBX) CEO Dr. Aoife Brennan on Q1 2021 Results - Earnings Call Transcript
- 05/13/2021
|
Synlogic Reports First Quarter Financial Results and Provides Business Update
- CAMBRIDGE, Mass., May 13, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today reported financial results for the first quarter ended March 31, 2021, and provided an update on its clinical and preclinical programs.
- 05/13/2021
|
3 Penny Stocks That Wall Street Wants You To Buy Now
- Penny stocks are very risky, which is why they have such low prices. Many of the companies in this risky part of the market will go bankrupt.
- 04/21/2021
|
7 Penny Stocks That May Not Be Penny Stocks For Long
- Many penny stocks are destined for bankruptcy, but there are some that will survive. Wall Street thinks these companies are undervalued.
- 04/21/2021
|
Synlogic Announces Pricing of Public Offering of Common Stock
- CAMBRIDGE, Mass., April 16, 2021 /PRNewswire/ -- Synlogic (Nasdaq: SYBX) a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $3.00 per share.
- 04/16/2021
|
Synlogic Announces Proposed Public Offering of Common Stock
- CAMBRIDGE, Mass., April 15, 2021 /PRNewswire/ -- Synlogic (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it has commenced an underwritten public offering of its common stock.
- 04/15/2021
|
Synlogic Presents Data Demonstrating Activity of a Solid Oral Formulation of SYNB1618 at American College of Medical Genetics (ACMG) Annual Meeting
- CAMBRIDGE, Mass., April 13, 2021 Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented data from the Phase 1 study of SYNB1618 for the treatment of Phenylketonuria (PKU) during the American College of Medical Genetics (ACMG) annual meeting, being held virtually April 13-16, 2021.
- 04/13/2021
|
Synlogic Presents Data from SYNB1891 Phase 1 Trial at American Association for Cancer Research (AACR) Annual Meeting
- CAMBRIDGE, Mass., April 10, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented data on SYNB1891 for the treatment of solid tumors and lymphoma during the American Association for Cancer Research (AACR) annual meeting, April 10-15, 2021.
- 04/10/2021
|
Synlogic to Present at Upcoming Virtual Banking and Industry Conferences
- CAMBRIDGE, Mass., April 1, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife Brennan, M.B.
- 04/01/2021
|
Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q4 2020 Results - Earnings Call Transcript
- Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q4 2020 Results - Earnings Call Transcript
- 03/25/2021
|
Synlogic Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
- CAMBRIDGE, Mass., March 25, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today reported financial results for the fourth quarter and full year ended December 31, 2020, and provided an update on programs and progress.
- 03/25/2021
|
Synlogic Announces SYNB8802 Will Advance to Phase 1B Proof of Concept Study After Proof of Mechanism Demonstrated in Dietary Hyperoxaluria
- CAMBRIDGE, Mass., March 24, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that SYNB8802 has achieved proof of mechanism in a Dietary Hyperoxaluria study in which healthy volunteers on a high oxalate and low calcium diet were treated with multiple ascending doses of SYNB8802.
- 03/24/2021
|
Synlogic Announces Fourth Quarter and Full Year 2020 Conference Call & Webcast
- CAMBRIDGE, Mass., March 16, 2021 /PRNewswire/ -- Synlogic, Inc. (NASDAQ: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Company will release its fourth quarter and full year 2020 financial results before the market opens on Thursday, March 25, 2021.
- 03/16/2021
|
Synlogic to Present at Upcoming Virtual Banking and Industry Conferences
- CAMBRIDGE, Mass., Feb. 15, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife Brennan, M.B. Ch.B., Synlogic's President and Chief Executive Officer, and other...
- 02/15/2021
|
Joint Team from MIT and Synlogic Named a Biotechnology Grand Challenge Winner by Air Force Research Laboratory
- CAMBRIDGE, Mass., Feb. 2, 2021 /PRNewswire/ -- A collaboration between MIT Voigt Lab and Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, has been recognized by the Air Force Research Laboratory (AFRL) as a...
- 02/02/2021
|
Do Options Traders Know Something About Synlogic (SYBX) Stock We Don't?
- Investors need to pay close attention to Synlogic (SYBX) stock based on the movements in the options market lately.
- 01/14/2021
|
Synlogic Outlines Upcoming Clinical Milestones
- CAMBRIDGE, Mass., Jan. 11, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today outlined significant clinical milestones for 2021 and provided an overview of recent progress. "With three...
- 01/11/2021
|
5 Biopharma Stocks Making Big Moves Monday
- Even as the broader market trades higher in reaction to the availability of the first coronavirus vaccine under emergency use authorization, a slew of biopharma stocks are moving on company-specific updates. Arvinas Inc (NASDAQ: ARVN): The smid-cap biopharma announced clinical program updates for its protein degraders ARV-471 and ARV-110.
- 12/14/2020
|
Why Is It Moving? Looking At Synlogic's Price Action Today
- Synlogic's (NASDAQ: SYBX) stock is trading up 17.18% to a price of $2.76. The stock's current volume for the day is 15.18 million, which is approximately 1159.03% of its previous 30-day average volume of 1.31 million.
- 12/14/2020
|
Synlogic Announces Advancement of SYNB1891 to Combination Arm Dosing with PD-L1 Checkpoint Inhibitor in the on-going Phase 1 Study for the Treatment of Solid Tumors and Lymphoma
- CAMBRIDGE, Mass., Dec. 14, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced SYNB1891 has advanced into the combination therapy stage of the ongoing Phase 1 trial. SYNB1891...
- 12/14/2020
|
Synlogic Appoints Michael Heffernan to its Board of Directors
- CAMBRIDGE, Mass., Dec. 9, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the appointment of Michael Heffernan to its board of directors. "We are delighted to welcome Mike...
- 12/09/2020
|
Synlogic Presents SYNB8802 for Enteric Hyperoxaluria at the American Institute of Chemical Engineers Conference on Microbiome Engineering
- CAMBRIDGE, Mass., Dec. 7, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it will present additional translational and in silico data on SYNB8802, a Synthetic Biotic...
- 12/07/2020
|
Synlogic to Present at Upcoming Virtual Banking Conference
- CAMBRIDGE, Mass., Nov. 18, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife Brennan, M.B. Ch.B., Synlogic's President and Chief Executive Officer, and other...
- 11/18/2020
|
Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q3 2020 Results - Earnings Call Transcript
- Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q3 2020 Results - Earnings Call Transcript
- 11/07/2020
|
Recap: Synlogic Q3 Earnings
- Shares of Synlogic (NASDAQ:SYBX) moved higher by 10.11% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 7.69% year over year to ($0.36), which beat the estimate of ($0.47).
- 11/05/2020
|
Synlogic Reports Third Quarter 2020 Financial Results and Provides Business Update
- CAMBRIDGE, Mass., Nov. 5, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today reported financial results for the third quarter ended Sept. 30, 2020, and provided an update on programs...
- 11/05/2020
|
